Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial

Simon Bowman, Robert I. Fox, Thomas Dörner, Xavier Mariette, Athena Papas, Thomas Grader‐Beck, Benjamin A. Fisher, Filipe Barcelos, Salvatore De Vita, Hendrik Schulze‐Koops, Robert J. Moots, G. Junge, J. Woznicki, Monika Sopala, Wen‐Lin Luo, Wolfgang Hueber